Incyte Corporation (0J9P.L)
USD 62.01
(1.56%)
USD 62.01
(1.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.44 Billion USD | 7.94% |
| 2022 | 3.18 Billion USD | 12.43% |
| 2021 | 2.83 Billion USD | 11.83% |
| 2020 | 2.53 Billion USD | 24.01% |
| 2019 | 2.04 Billion USD | 14.36% |
| 2018 | 1.78 Billion USD | 22.72% |
| 2017 | 1.45 Billion USD | 39.06% |
| 2016 | 1.04 Billion USD | 44.13% |
| 2015 | 726.77 Million USD | 42.93% |
| 2014 | 508.49 Million USD | 43.51% |
| 2013 | 354.31 Million USD | 19.34% |
| 2012 | 296.9 Million USD | 214.33% |
| 2011 | 94.45 Million USD | -44.4% |
| 2010 | 169.87 Million USD | 1733.55% |
| 2009 | 9.26 Million USD | 136.41% |
| 2008 | 3.91 Million USD | -88.62% |
| 2007 | 34.44 Million USD | 24.59% |
| 2006 | 27.64 Million USD | 252.32% |
| 2005 | 7.84 Million USD | -44.54% |
| 2004 | 14.14 Million USD | -69.96% |
| 2003 | 47.09 Million USD | -53.66% |
| 2002 | 101.61 Million USD | -53.66% |
| 2001 | 219.26 Million USD | -4.26% |
| 2000 | 229 Million USD | 26.04% |
| 1999 | 181.7 Million USD | 19.07% |
| 1998 | 152.6 Million USD | 54.45% |
| 1997 | 98.8 Million USD | 104.55% |
| 1996 | 48.3 Million USD | 226.35% |
| 1995 | 14.8 Million USD | 1245.45% |
| 1994 | 1.1 Million USD | 133.33% |
| 1993 | -3.3 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 1.05 Billion USD | 10.63% |
| 2024 Q1 | 819.88 Million USD | -13.11% |
| 2024 Q2 | 950.77 Million USD | 15.96% |
| 2023 Q3 | 858.93 Million USD | -3.09% |
| 2023 FY | 3.44 Billion USD | 7.94% |
| 2023 Q4 | 943.54 Million USD | 9.85% |
| 2023 Q1 | 751.85 Million USD | -13.33% |
| 2023 Q2 | 886.31 Million USD | 17.88% |
| 2022 Q1 | 690.62 Million USD | -15.67% |
| 2022 FY | 3.18 Billion USD | 12.43% |
| 2022 Q4 | 867.53 Million USD | 12.86% |
| 2022 Q3 | 768.7 Million USD | -10.69% |
| 2022 Q2 | 860.76 Million USD | 24.64% |
| 2021 Q2 | 667.7 Million USD | 16.02% |
| 2021 Q3 | 773.08 Million USD | 15.78% |
| 2021 Q4 | 818.97 Million USD | 5.94% |
| 2021 FY | 2.83 Billion USD | 11.83% |
| 2021 Q1 | 575.49 Million USD | -23.59% |
| 2020 Q3 | 586.34 Million USD | -10.43% |
| 2020 Q1 | 541.18 Million USD | -1.09% |
| 2020 Q2 | 654.64 Million USD | 20.96% |
| 2020 FY | 2.53 Billion USD | 24.01% |
| 2020 Q4 | 753.18 Million USD | 28.45% |
| 2019 Q2 | 500.52 Million USD | 5.31% |
| 2019 Q1 | 475.26 Million USD | -5.33% |
| 2019 FY | 2.04 Billion USD | 14.36% |
| 2019 Q3 | 521.54 Million USD | 4.2% |
| 2019 Q4 | 547.17 Million USD | 4.91% |
| 2018 Q3 | 424.88 Million USD | -14.45% |
| 2018 Q4 | 502.03 Million USD | 18.16% |
| 2018 Q1 | 364.17 Million USD | -13.66% |
| 2018 FY | 1.78 Billion USD | 22.72% |
| 2018 Q2 | 496.66 Million USD | 36.38% |
| 2017 Q2 | 306.18 Million USD | -17.08% |
| 2017 FY | 1.45 Billion USD | 39.06% |
| 2017 Q1 | 369.25 Million USD | 20.32% |
| 2017 Q3 | 359.49 Million USD | 17.41% |
| 2017 Q4 | 421.79 Million USD | 17.33% |
| 2016 Q3 | 249.26 Million USD | 6.56% |
| 2016 Q2 | 233.92 Million USD | -9.14% |
| 2016 FY | 1.04 Billion USD | 44.13% |
| 2016 Q1 | 257.45 Million USD | 9.94% |
| 2016 Q4 | 306.88 Million USD | 23.12% |
| 2015 Q4 | 234.17 Million USD | 30.41% |
| 2015 Q2 | 156.73 Million USD | 0.27% |
| 2015 FY | 726.77 Million USD | 42.93% |
| 2015 Q3 | 179.57 Million USD | 14.57% |
| 2015 Q1 | 156.3 Million USD | 28.6% |
| 2014 Q1 | 89.62 Million USD | -7.51% |
| 2014 Q3 | 197.92 Million USD | 99.13% |
| 2014 Q2 | 99.39 Million USD | 10.9% |
| 2014 Q4 | 121.54 Million USD | -38.59% |
| 2014 FY | 508.49 Million USD | 43.51% |
| 2013 Q4 | 96.9 Million USD | 14.05% |
| 2013 Q2 | 101.51 Million USD | 43.13% |
| 2013 Q1 | 70.92 Million USD | -37.64% |
| 2013 FY | 354.31 Million USD | 19.34% |
| 2013 Q3 | 84.96 Million USD | -16.3% |
| 2012 Q2 | 86.52 Million USD | 139.23% |
| 2012 Q4 | 113.74 Million USD | 88.13% |
| 2012 Q3 | 60.46 Million USD | -30.12% |
| 2012 Q1 | 36.16 Million USD | 25.19% |
| 2012 FY | 296.9 Million USD | 214.33% |
| 2011 Q1 | 31.97 Million USD | -62.77% |
| 2011 FY | 94.45 Million USD | -44.4% |
| 2011 Q4 | 28.89 Million USD | 72.15% |
| 2011 Q3 | 16.78 Million USD | -0.17% |
| 2011 Q2 | 16.81 Million USD | -47.42% |
| 2010 FY | 169.87 Million USD | 1733.55% |
| 2010 Q4 | 85.87 Million USD | 408.95% |
| 2010 Q3 | 16.87 Million USD | -66.15% |
| 2010 Q2 | 49.84 Million USD | 188.33% |
| 2010 Q1 | 17.28 Million USD | 151.79% |
| 2009 Q4 | 6.86 Million USD | 631.2% |
| 2009 FY | 9.26 Million USD | 136.41% |
| 2009 Q1 | 671 Thousand USD | -28.46% |
| 2009 Q2 | 789 Thousand USD | 17.59% |
| 2009 Q3 | 939 Thousand USD | 19.01% |
| 2008 Q1 | 1.3 Million USD | -86.6% |
| 2008 Q4 | 938 Thousand USD | -11.59% |
| 2008 FY | 3.91 Million USD | -88.62% |
| 2008 Q2 | 614 Thousand USD | -53.02% |
| 2008 Q3 | 1.06 Million USD | 72.8% |
| 2007 Q1 | 7.42 Million USD | 5.19% |
| 2007 Q2 | 10.57 Million USD | 42.5% |
| 2007 Q3 | 6.69 Million USD | -36.74% |
| 2007 Q4 | 9.75 Million USD | 45.77% |
| 2007 FY | 34.44 Million USD | 24.59% |
| 2006 Q2 | 6.85 Million USD | 6.03% |
| 2006 Q4 | 7.05 Million USD | -2.92% |
| 2006 Q3 | 7.26 Million USD | 6.02% |
| 2006 Q1 | 6.46 Million USD | 528.89% |
| 2006 FY | 27.64 Million USD | 252.32% |
| 2005 Q1 | 2.91 Million USD | 377.09% |
| 2005 Q4 | 1.02 Million USD | -16.29% |
| 2005 Q2 | 2.67 Million USD | -8.2% |
| 2005 Q3 | 1.22 Million USD | -54.11% |
| 2005 FY | 7.84 Million USD | -44.54% |
| 2004 FY | 14.14 Million USD | -69.96% |
| 2004 Q1 | 6.64 Million USD | -35.51% |
| 2004 Q2 | 5.16 Million USD | -22.26% |
| 2004 Q3 | 3.39 Million USD | -34.28% |
| 2004 Q4 | -1.05 Million USD | -131.01% |
| 2003 Q2 | 11.03 Million USD | -11.78% |
| 2003 Q4 | 10.29 Million USD | -22.27% |
| 2003 Q3 | 13.24 Million USD | 20.05% |
| 2003 Q1 | 12.5 Million USD | -40.85% |
| 2003 FY | 47.09 Million USD | -53.66% |
| 2002 Q4 | 21.14 Million USD | -5.54% |
| 2002 Q2 | 29.05 Million USD | 0.16% |
| 2002 FY | 101.61 Million USD | -53.66% |
| 2002 Q3 | 22.39 Million USD | -22.95% |
| 2002 Q1 | 29.01 Million USD | -47.03% |
| 2001 Q3 | 57.31 Million USD | 2.26% |
| 2001 Q2 | 56.05 Million USD | -12.04% |
| 2001 FY | 219.26 Million USD | -4.26% |
| 2001 Q4 | 54.77 Million USD | -4.44% |
| 2001 Q1 | 63.72 Million USD | -0.58% |
| 2000 Q3 | 61.61 Million USD | 13.2% |
| 2000 Q2 | 54.43 Million USD | 11.38% |
| 2000 FY | 229 Million USD | 26.04% |
| 2000 Q1 | 48.86 Million USD | -7.97% |
| 2000 Q4 | 64.09 Million USD | 4.02% |
| 1999 Q2 | 44.3 Million USD | 3.02% |
| 1999 Q3 | 41.3 Million USD | -6.77% |
| 1999 Q4 | 53.1 Million USD | 28.57% |
| 1999 Q1 | 43 Million USD | 1.42% |
| 1999 FY | 181.7 Million USD | 19.07% |
| 1998 Q4 | 42.4 Million USD | 8.72% |
| 1998 Q2 | 37.1 Million USD | 8.8% |
| 1998 FY | 152.6 Million USD | 54.45% |
| 1998 Q1 | 34.1 Million USD | 14.43% |
| 1998 Q3 | 39 Million USD | 5.12% |
| 1997 Q3 | 25.4 Million USD | 7.63% |
| 1997 FY | 98.8 Million USD | 104.55% |
| 1997 Q4 | 29.8 Million USD | 17.32% |
| 1997 Q1 | 20.1 Million USD | 22.56% |
| 1997 Q2 | 23.6 Million USD | 17.41% |
| 1996 Q1 | 6.6 Million USD | 13.79% |
| 1996 Q3 | 14.9 Million USD | 67.42% |
| 1996 FY | 48.3 Million USD | 226.35% |
| 1996 Q4 | 16.4 Million USD | 10.07% |
| 1996 Q2 | 8.9 Million USD | 34.85% |
| 1995 Q3 | 3.5 Million USD | 34.62% |
| 1995 Q2 | 2.6 Million USD | 36.84% |
| 1995 Q4 | 5.8 Million USD | 65.71% |
| 1995 Q1 | 1.9 Million USD | 375.0% |
| 1995 FY | 14.8 Million USD | 1245.45% |
| 1994 Q1 | 100 Thousand USD | 110.0% |
| 1994 Q2 | -1.3 Million USD | -1400.0% |
| 1994 FY | 1.1 Million USD | 133.33% |
| 1994 Q4 | 400 Thousand USD | 33.33% |
| 1994 Q3 | 300 Thousand USD | 123.08% |
| 1993 FY | -3.3 Million USD | 0.0% |
| 1993 Q3 | -800 Thousand USD | 0.0% |
| 1993 Q4 | -1 Million USD | -25.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 3556.966% |
| Dynavax Technologies Corporation | 182.11 Million USD | -1789.252% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -23157.057% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 87.028% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -556.936% |
| Perrigo Company plc | 1.68 Billion USD | -104.752% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1099348.882% |
| Illumina, Inc. | 2.74 Billion USD | -25.388% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 77.4% |
| Nektar Therapeutics | 53.47 Million USD | -6333.765% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 36067.479% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 34.326% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -34162.587% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 17566.11% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -80.671% |
| Waters Corporation | 1.76 Billion USD | -95.359% |
| Biogen Inc. | 7.3 Billion USD | 52.882% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 7691.062% |
| Adicet Bio, Inc. | -6.09 Million USD | 56522.581% |
| Evolus, Inc. | 140.52 Million USD | -2348.407% |
| bluebird bio, Inc. | -4.03 Million USD | 85475.906% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 4137.562% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -4608.896% |
| FibroGen, Inc. | 128.9 Million USD | -2569.156% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 0.703% |
| Homology Medicines, Inc. | -7.22 Million USD | 47695.089% |
| Geron Corporation | -123.5 Million USD | 2885.883% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -126.674% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 11139.164% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -850.377% |
| Myriad Genetics, Inc. | 476.4 Million USD | -622.219% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 69.556% |
| OPKO Health, Inc. | 318.12 Million USD | -981.533% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1178404.452% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 962.763% |
| Zoetis Inc. | 5.83 Billion USD | 41.024% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -1139187.748% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -58.623% |
| Exelixis, Inc. | 1.75 Billion USD | -95.752% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 60.025% |
| uniQure N.V. | 2.21 Million USD | -155234.041% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1135627.723% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -1307.017% |
| Verastem, Inc. | -62 Thousand USD | 5549533.871% |
| Imunon, Inc. | -720 Thousand USD | 477964.598% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -341.951% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -214.791% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -86.243% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -622.986% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -440.225% |
| TG Therapeutics, Inc. | 219.1 Million USD | -1470.298% |
| Blueprint Medicines Corporation | 236.58 Million USD | -1354.303% |
| Insmed Incorporated | 239.63 Million USD | -1335.787% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -19766.326% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -900.479% |